Abstract
Background: Pharmacists have the authorization to prescribe medications for the treatment of uncomplicated urinary tract infections (UTI) in some provinces. However, there are limited data on the outcomes of this care by pharmacists. Our objective was to evaluate the effectiveness, safety and patient satisfaction with pharmacist prescribing and care in patients with uncomplicated UTI. Methods: We conducted a prospective registry trial in 39 community pharmacies in the Canadian province of New Brunswick. Adult patients were enrolled if they presented to the pharmacy with either symptoms of UTI with no current antibacterial treatment (Pharmacist-Initial Arm) or if they presented with a prescription for an antibacterial to treat UTI from another health care provider (Physician-Initial Arm). Pharmacists assessed patients and if they had complicating factors or red flags for systemic illness or pyelonephritis, they were excluded from the study. Pharmacists either prescribed antibacterial therapy, modified antibacterial therapy, provided education only or referred to physician, as appropriate. The primary outcome was clinical cure at 2 weeks and the secondary outcomes included adverse events and patient satisfaction. Results: A total of 750 patients were enrolled (87.4% in the Pharmacist-Initial Arm), average age was 40.9 (SD 16.0) years. Clinical cure was achieved in 88.9% of patients. Of those that did not have sustained symptom resolution, most (5.5% overall) had symptom recurrence after completion of therapy. Adverse events were reported by 7.2% of patients and 88.9% of those continued their medication. Most adverse events were gastrointestinal-related and transient. The patient satisfaction survey reflected very high levels of satisfaction for the care they received, as well as for trust and accessibility of the pharmacist. Conclusion: Pharmacist management of uncomplicated UTI is effective, safe, and patient satisfaction appears very high.
| Original language | English |
|---|---|
| Pages (from-to) | 305-314 |
| Number of pages | 10 |
| Journal | Canadian Pharmacists Journal |
| Volume | 151 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Sept 1 2018 |
Bibliographical note
Funding Information:Author Contributions: All authors contributed to the study concept and design. N. P. Beahm obtained funding from the secondary sponsor, provided education to the study pharmacists, was involved in analysis and interpretation of data, drafted the initial version of the manuscript and critically revised the manuscript for intellectual content. D. J. Smyth critically revised the manuscript for intellectual content. R. T. Tsuyuki initiated the project, obtained funding from both sponsors, supervised the study conduct and critically revised the manuscript for intellectual content. All authors approved the final draft of the manuscript.
Funding Information:
The authors also acknowledge the support of the Alberta SPOR Support Unit Consultation and Research Services Platform (www. absporu.ca) and the work of the biostatistical and data management staff at the EPICORE Centre, University of Alberta (www. epicore.ualberta.ca).
Publisher Copyright:
© The Author(s) 2018.
ASJC Scopus Subject Areas
- Pharmacy
- Pharmaceutical Science
PubMed: MeSH publication types
- Journal Article